A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
The DOI matches its Crossref record.
Abstract
2010b Background: Effective 2nd-line therapies are absent in GBM leading to poor survival. VEGF upregulation is implicated in GBM tumorigenesis. In a single-arm PhII trial of BV + CPT in recurrent GBM, activity was demonstrated, warranting further investigation of clinical benefit of BV alone, and in combination with CPT (Vredenburgh J, JCO 2007). Methods: From June 2006 to Feb 2007, 167 patients (pts) with recurrent GBM were randomized 1:1 to BV (10 mg/kg q 2 wks) (Arm 1, n=85) or BV + CPT (340 mg/m2 if enzyme-inducing anti- epileptic drugs (AEDs) and 125 mg/m2 for non-AEDs) (Arm 2, n=82), stratified by KPS: 70–80, 90–100, and relapse (1st or 2nd). The co- primary endpoints were PFS6 (defined at 24-weeks) and objective response rate (ORR) determined by an independent radiology facility (IRF), with secondary endpoints of safety, PFS, and duration of response determined by IRF, and overall survival. The trial provided approximately 80% power to detect 13% improvement in PFS6 from an assumed rate of 15%, and 90% power to detect 13% improvement in ORR from assumed rates of 5% (Arm 1) and 10% (Arm 2) (2-sided significance level of 0.025). Results: Clinical outcomes are shown in Table 1. Median OS was based on 61.2% of deaths for BV alone and 67.1% of deaths for BV+CPT. One intracranial hemorrhage occurred in Arm 1 (Gr 1; 1.2%) and one in Arm 2 (Gr 4; 1.3%) during planned treatment period. The dose of corticosteroid required diminished from baseline to cycle 4 (Table 1). Benchmarking OS to that in a national GBM database is ongoing. Ä in KPS and neurocognitive function from baseline, and post-progression response will be presented. Conclusions: Both the PFS6 and OS of >9 months with BV alone or with CPT provides encouraging evidence of significant activity in this poor prognosis population. In addition, the reduction in corticosteroid use has the potential to provide benefit to patients. Randomized Subjects BV (n=85) BV + CPT (n=82) Median OS months (95% CI) 9.7 (8.2–11.8) 8.9 (7.8–11.9) PFS6 % (97.5% CI) 35.1 (23.2–47.0) 50.2 (36.6–63.8) ORR % (97.5% CI) 20 (12.7–29.5) 32.9 (23.4–43.5) Treated Subjects BV (n=84) BV + CPT (n=79) Grade >3 toxicities, % 47.6 67.1 Grade 5 AEs, % 2.4 1.3 BV discontinuation due to AEs, % 3.5 13.9 Corticosteroid dose (mg/kg) BV (n=84) BV + CPT (n=79) N, Mean (SD) Day 1 44, 7.3 (7.37) 46, 8.0 (4.96) Day 42 41, 5.0 (5.59) 44, 7.5 (5.71) Day 84 34, 3.1 (2.80) 34, 4.7 (3.68) Day 126 21, 2.7 (3.13) 21, 3.9 (2.60) Day 168 12, 1.1 (1.04) 15, 4.4 (4.13) No significant financial relationships to disclose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Self-citationCentral Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Self-citationWick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
de Groot, J. F., Fuller, G., Kumar, A. J., Piao, Y., Eterovic, K., Ji, Y., & Conrad, C. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop027 · Cited by 509
Gutin, P. H., Iwamoto, F. M., Beal, K., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S., Yamada, Y., Chang, J., & Abrey, L. E. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.043 · Cited by 370
Self-citation
Metadata
- Authors
- Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K., Maoxia, Z., Dimery, I., & Friedman, H. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-20
- Volume
- 26
- Issue
- 15_suppl
- Pages
- 2010b-2010b
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2338264812
- Cited by
- 144
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). https://app.cochat.ai/papers/10.1200/jco.2008.26.15_suppl.2010b
- The paper
- Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K., Maoxia, Z., Dimery, I., & Friedman, H. S. (2008). A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.26.15_suppl.2010b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.